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Objective: To develop a short-term in vivo model in rats, with an enzyme-linked immunosorbent assay
(ELISA) readout for speciﬁc aggrecanase-cleaved aggrecan fragments, to facilitate testing of aggrecanase
inhibitors.
Methods: Monosodium iodoacetate (MIA), a metabolic inhibitor, was injected into the right knee joint of
male Lewis rats and the release of aggrecanase-cleaved fragments of aggrecan containing the NITEGE or
ARGN neoepitope was measured in the synovial ﬂuid at 7 days post MIA injection using novel ELISAs. The
ELISAs utilize a commercial antibody directed against the hyaluronic-acid binding region (HABR) of
aggrecan, in combination with either an a-NITEGE antibody (NITEGE ELISA) or an a-ARGS/BC3 antibody
(ARGS ELISA), to detect aggrecanase-cleavage of aggrecan within the interglobular domain (IGD).
Aggrecan fragments present in in vitro digests, in cytokine-treated cartilage explant culture supernatants
and in rat synovial ﬂuid lavage samples were detected and quantiﬁed using the two ELISAs. Small
molecule inhibitors of aggrecanase activity were dosed orally on days 3e7 to determine their ability to
inhibit MIA-induced generation of the NITEGE and ARGN neoepitopes measured in the rat synovial ﬂuid.
Results: The NITEGE assay was shown to speciﬁcally detect the N-terminal fragment of aggrecan
comprising the G1 domain and the NITEGE neoepitope sequence. This assay can readily measure
aggrecanase-cleaved bovine, human and rat aggrecan without the need for deglycosylation. The ARGS
assay speciﬁcally detects C-terminal fragments of aggrecan comprising the ARGS/ARGN neoepitope and
the G2 domain. Keratan sulfate (KS) residues of aggrecan interfere with this ELISA, and hence this assay
works well with native rat articular cartilage aggrecan (that lacks KS residues) and with deglycosylated
bovine and human aggrecan. Injection of MIA into the rat knee joints resulted in a time-dependent
increase in the release of aggrecanase-cleaved aggrecan fragments into the synovial ﬂuid and treatment
with an aggrecanase inhibitor resulted in a dose-dependent inhibition of the generation of these
neoepitopes.
Conclusions: We have established a short-term in vivo model in rats that involves measurement of
synovial ﬂuid biomarkers that are dependent on aggrecanase activity in the joint. The short duration of
the model combined with the mechanistic biomarker readout makes it very useful for the initial in vivo
screening of aggrecanase inhibitors prior to testing them in time and resource-intensive disease models
of osteoarthritis (OA).
 2010 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.: Kannan Thirunavukkarasu,
pany, Indianapolis, IN 46285.
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Articular cartilage is a smooth weight bearing tissue that covers
the ends of long bones and facilitates the frictionless movement of
one bone over the other in diarthrodial joints. Aggrecan is themajor
proteoglycan in articular cartilage that is responsible for the
compressibility and elasticity properties of cartilage. One of theublished by Elsevier Ltd. All rights reserved.
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aggrecan by proteolytic cleavage1,2. Two members of the ADAMTS
(A Disintegrin And Metalloproteinase with ThromboSpondin
motifs) family of proteins, ADAMTS-4 (aggrecanase-1) and
ADAMTS-5 (aggrecanase-2) are thought to play a critical role in this
degradative process3 in humans. However, gene knockout studies
in mice implicate a major role for ADAMTS-5, but not ADAMTS-4, in
aggrecan degradation that occurs in surgical and inﬂammatory
mouse models of OA4e7. Inhibitors of these enzymes are expected
to block cartilage destruction associated with OA8.
ADAMTS-4 and -5 are known to cleave aggrecan at ﬁve locations
in the molecule9,10. Cleavage within the interglobular domain (IGD)
(NITEGE373-374ARGS) is considered to be the most destructive as it
results in release of the functional C-terminal end containing
sulfated sugar chains. Aggrecanase-generated aggrecan fragments
are found in synovial ﬂuids from patients with OA, joint injury and
inﬂammatory joint disease11, implicating a role for aggrecanases in
the pathogenesis of these joint disorders. Detection and quantita-
tion of these fragments in biological ﬂuids (synovial ﬂuid, serum
and/or urine) may serve as biomarkers of disease status of the joint
and is likely to facilitate the identiﬁcation of aggrecanase inhibitors.
OA is a disease that develops over decades in humans. This
slowly progressing nature of the disease warrants the need for
animal models that also show slow progression of the disease to
make them relevant for testing disease modifying drugs (e.g.,
spontaneous models of arthritis described in mice and guinea
pigs12,13). However, the long duration of these animal models
(several months) makes them less suitable for routine preclinical
testing of drugs. On the other hand, a number of surgical models
have been described that show a relatively rapid progression of
the disease [e.g., mouse menisectomy, rat meniscal tear, rabbit
anterior cruciate ligament transection (ACLT), etc.]12,13. Both the
spontaneous and surgical models are very resource-intensive as
they currently rely on histological readouts to determine the
efﬁcacy of pharmacological agents tested. So, there is a need to
develop short-term in vivo models with a simpler readout of
mechanistic activity of compounds to enable rapid testing in
a screening mode. Compounds that show mechanism-based
activity can then be tested in the labor intensive surgical/spon-
taneous OA models.
Malfait et al.14 recently described a short-term in vivo model in
rats that involves intra-articular injection of TNF-a into the knee
joints followed by synovial lavage to measure glycosaminoglycans
(GAGs) using a dye-binding assay and speciﬁc aggrecanase-
generated aggrecan neoepitopes using Western blot analysis. They
have demonstrated the potential utility of this model for testing
aggrecanase inhibitors and other agents that block proteoglycan
degradation. Janusz et al.15 described the time course of aggrecan
and type II collagen degradation in response to monosodium
iodoacetate (MIA) injection into the rat knee joint by Western blot
analysis of articular cartilage extracts using neoepitope antibodies.
However, Western blot analysis is not very quantitative, some-
what labor intensive and has a low throughput. Pratta et al.16
described a sandwich enzyme-linked immunosorbent assay
(ELISA) that makes use of an a-keratan sulfate (KS) antibody and
the a-ARGS antibody17. This assay has been shown to be useful for
measuring ARGS-containing fragments in human synovial
ﬂuid16,18. However, the dependence of this assay on the presence
of KS substitutions in aggrecan, makes it unsuitable for measuring
rat aggrecan and its fragments as they do not contain KS resi-
dues19e21. To overcome these limitations, we have now developed
a short-term in vivo model of aggrecanase activity in rats that
combines MIA injection into the knee joint with two novel ELISA
assays that can quantify aggrecanase-cleaved NITEGE and ARGN-
containing fragments released into the synovial ﬂuid. We showthat oral administration of small molecule aggrecanase inhibitors
can dose-dependently inhibit the generation of these neoepitopes,
thereby demonstrating the utility of this model for testing the oral
bioavailability and pharmacodynamic activity of compounds prior
to testing them in more resource-intensive OA disease models.Materials and methods
Aggrecanase-mediated cleavage of aggrecan within the IGD at
the E373eA374 bond results in the generation of the NITEGE373 and
374ARGS neoepitopes22. The G1 and G2 domains of aggrecan
contain two copies of a hyaluronic-acid binding region (HABR)
motif (also known as proteoglycan tandem repeat (PTR))23,24. We
made use of the HABR motifs present in the G1 and G2 domains to
develop two novel sandwich ELISAs using an a-HABR antibody that
recognizes the G1 and G2 domains of aggrecan, in combination
with either the NITEGE or ARGS neoepitope-speciﬁc antibody.Aggrecan and recombinant aggrecanase-1 (ADAMTS-4) protein
Rat aggrecanwas puriﬁed from chondrosarcoma tissue obtained
from rats that were injected with tumors. Human articular cartilage
aggrecan was obtained from Dr. John Sandy (Rush University, Chi-
cago) and bovine articular cartilage aggrecan was purchased from
Sigma. Truncated human recombinant ADAMTS-4 (213-579) with
a C-terminal oligohistidine tag was expressed in HEK 293 cells and
puriﬁed.Antibodies
A monoclonal antibody directed against the HABR of aggrecan
(a-HABR antibody) was purchased from Invitrogen (Carlsbad, CA)
(catalog # AHP0022). This antibody recognizes both undigested
and aggrecanase-digested bovine, human and rat aggrecan binds to
both the G1 and G2 domains in aggrecan. The a-HABR antibodywas
directly conjugated with horseradish peroxidase (HRP) using a HRP
conjugation kit (Alpha Diagnostic International). The monoclonal
a-NITEGE antibody (681-3)25 was raised against the NITEGE373
neoepitope sequence that results from aggrecanase-cleavage at the
373EeA374 bond within the IGD of aggrecan. The monoclonal anti-
body BC3 that recognizes the 374ARGS (ARGN in rat) neoepitope
sequence17 was obtained from Novus Biologicals and puriﬁed on
a Protein G column.In vitro digestion of aggrecan
Lyophilized bovine articular, human articular and rat chon-
drosarcoma aggrecanwas solubilized to a concentration of 1 mg/ml
in assay buffer (50 mM Tris pH 7.5, 10 mM CaCl2, 100 mM NaCl,
0.02% Brij, 0.1% BSA). The aggrecan was digested at 37C 10 nM
ADAMTS-4. Aliquots were removed at 2, 4, 6 and 24 h and the
reaction was quenched with 83.33 mM EDTA. The resulting frag-
ments were characterized by Western blot analysis26 and ELISA.
The digests were shown to contain speciﬁc aggrecanase-generated
aggrecan fragments using the a-NITEGE and a-ARGS (BC3)
antibodies.In vitro aggrecanase and matrix metalloprotease (MMP) assays
The IC50 of inhibitors for inhibiting aggrecanase (ADAMTS-4
and ADAMTS-5) and MMP activity was determined as described
before27,28.
C.A. Swearingen et al. / Osteoarthritis and Cartilage 18 (2010) 1159e1166 1161Bovine articular cartilage (BAC) explant assay
BACwas obtained from Covance Research Products (Denver, PA).
Cartilage slices were punched with sterile 4 mm dermal biopsy
punches (Marina Medical Instruments), weighed and cultured
individually in 96 well plates. Aggrecan degradation was initiated
by the addition of 50 ng/ml IL-1a in serum free media in the
presence or absence of a broad-spectrum inhibitor of MMPs and
aggrecanases (CP-669685)29,30, or broad-spectrum inhibitors of
MMPs that have weak activity against aggrecanases [GM-6001
(Calbiochem), Marimastat or RS-13083031 (Table I)]. Conditioned
medium was collected 72 h later and analyzed by di-methyl
methylene blue (DMMB) dye-binding assay and by the NITEGE
neoepitope ELISA (described below).DMMB dye-binding assay
16 mg of DMMB was dissolved in 5 ml of ethanol. 2 ml of formic
acid and 2 g of sodium formate were then added and the solution
was brought up to 1 l with distilled water and stored at room
temperature, protected from light. 1 mg/ml shark chondroitin
sulfate was prepared for use as a standard (for s-GAG levels) and
stored at 80C in aliquots. The DMMB assay was done in 96 well
plates. The GAG standard was diluted in sample buffer (culture
medium) to get a concentration range from 80 mg/ml and below in
a ﬁnal volume of 20 ml. 20 ml of the sample (diluted to the desired
level) was mixed with 250 ml of DMMB dye and the plates were
read immediately on a plate reader at 525 nm. The data were
normalized to the wet weight of cartilage.Human synovial ﬂuid samples
Human synovial ﬂuid samples were obtained from the knee
joints of 18 patients (age range: 54e87) undergoing knee replace-
ment surgery (St. Francis Hospital, Beech Grove, IN), under
a protocol approved by the institutional review board (IRB), with
informed consent from the patients. The synovial ﬂuid samples
were treated with hyaluronidase to reduce viscosity prior to using
them in the ELISA assay. Hyaluronidase (Sigma H-1136) was dis-
solved in 10 ml of 1 M Sodium Acetate pH 6.5 containing 10
protease inhibitors (Sigma P2714) to a concentration of 67.4 units/
ml. 100 ml of this solution was rocked at 37C for 3 h with 900 ml of
human synovial ﬂuid (ﬁnal concentration of 6.74 units hyaluroni-
dase per ml human synovial ﬂuid). 1 ml of synovial ﬂuid was then
deglycosylated with the addition of 1 unit of chondroitinase ABC
(Seikagaku #100330) and rocked at 37C for 3 h. The samples were
then treated with 1 unit keratanase (Seikagaku #100810) and
0.01 units keratanase II (Seikagaku #100812) and rocked at 37C for
3 h. The samples were aliquoted and stored frozen at 80C until
needed for the ELISA assay.
For peptide competition experiments to demonstrate signal
speciﬁcity, either a 16-mer NITEGE-containing peptide
(WPDMELPLPRNITEGE) or a 22-mer ARGS-containing peptide
(ARGSVILTVKPIFEVSPSPLKG) was used.Table I
IC50 of inhibitors for puriﬁed human aggrecanases (ADAMTS-4 and -5) and MMPs (valu
Compound hADAMTS-4 hADAMTS-5 hMMP1
CP-669685 1.1 0.72 416
GM-6001 52.9 52.2 0.598
Marimastat 68 98.1 <5
RS-130830 270 57.5 686
Compound A 7.5 16.9 11,000Sandwich ELISA assays
For the NITEGE ELISA, the a-NITEGE monoclonal antibody was
immobilized on white high binding ELISA plates (Nunc) overnight
at 4C. Following blocking, samples (in vitro digests, cartilage
explant culture supernatants, human synovial ﬂuid or rat synovial
ﬂuid lavage) were added to the plate and fragments with a C-ter-
minal NITEGE sequence were captured. The captured fragments
were detected using the HRP-conjugated a-HABR monoclonal
antibody. For the ARGS ELISA, the a-HABR antibody (not HRP-
conjugated) was used for capturing the aggrecan fragments and an
HRP-conjugated BC3 antibody (that recognizes the ARGS or ARGN
sequence) was used as the detection antibody. The ELISA signal was
measured using the Supersignal ELISA femto maximum sensitivity
substrate (Pierce) and read on a Victor luminometer. The amount of
aggrecan fragments present in the sample was determined based
on a standard curve generated with aggrecanase-digested rat
chondrosarcoma aggrecan (850 mg/ml stock diluted in antibody
dilution buffer).
MIA injection model in rats
MIA (Sigma, catalog # I2512, sodium salt) was prepared fresh on
the day of use at 3 mg in 50 ml sterile 0.9% saline. 7e8-week-old
male Lewis rats were anesthetized and injected intra-articularly
with MIA into the right knee (to induce endogenous aggrecanase
activity and the release of aggrecan fragments into the synovial
ﬂuid) and saline in the left (contralateral) knee on day 0. Aggre-
canase inhibitor (3, 10 or 30 mg/kg) or vehicle [1% hydroxyethyl
cellulose (HEC); 0.25% Tween 80; 0.05% antifoam] was dosed orally,
twice a day starting from day 3. A single dose of compound was
given on day 7, the animals were sacriﬁced 4 h later, and the knee
joints were lavaged with 200 ml saline. The synovial lavage was
assayed for aggrecanase-cleaved fragments of aggrecan using the
NITEGE and ARGS sandwich ELISAs. The amount of aggrecan frag-
ments present in the synovial lavage was determined based on
a standard curve generated with aggrecanase-digested rat aggre-
can. Statistical analysis was performed using Dunnett’s test.
All animals studies were performed under a protocol approved
by Eli Lilly’s institutional animal care and use committee and
animals were cared for in accordance with the institutional
guidelines.
Results
Sandwich ELISAs to measure aggrecanase-cleaved aggrecan
fragments
The NITEGE ELISA detects the N-terminal fragment of aggrecan
comprising the G1 domain and the NITEGE neoepitope sequence. In
this ELISA, the aggrecan fragments were ﬁrst captured with the
a-NITEGE antibody, followed by detection of the captured frag-
ments with the a-HABR antibody (schematic shown in Fig. 1(a)).
Since the N-terminal region of aggrecan is sparsely glycosylated, it
is possible to detect native aggrecan fragments without the needes shown are in nM)
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Fig. 1. (a) Schematic of the epitopes recognized in the NITEGE and ARGS ELISAs to
measure aggrecanase-generated aggrecan fragments. HABR denotes the motifs present
in the G1 and G2 domains of aggrecan. (b) Time-dependent increase in NITEGE neo-
epitope generation upon ADAMTS-4 digestion of bovine, human and rat aggrecan in
the NITEGE ELISA. BAA: bovine articular aggrecan; HAA: human articular aggrecan; RA:
rat aggrecan; TS4: ADAMTS-4/aggrecanase-1. (c) Effects of KS on the ability of the
ARGS ELISA to measure ADAMTS-4-digested rat or human aggrecan. Rat and human
aggrecan were digested overnight with ADAMTS-4 as indicated in Materials and
methods. ADAMTS-4-digested rat aggrecan which lacks KS can be measured using
this ELISA in the native state without the need for deglycosylation. ADAMTS-4-digested
human articular aggrecan must be deglycosylated to remove KS residues to be
measured in this ELISA system. Data shown are the mean standard deviation of
representative digests done in duplicate.
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Fig. 2. Measurement of aggrecanase-cleaved aggrecan fragments in BAC explant
cultures treated with IL-1a  aggrecanase/metalloprotease inhibitors. Conditioned
media were collected 72 h post treatment and the levels of aggrecanase-cleaved
fragments of aggrecan were measured by the NITEGE ELISA (with pooled samples) (a)
and s-GAG levels were measured by the DMMB assay (b). Data shown are the
mean standard error of a representative experiment (n¼ 8 explants/treatment).
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aggrecan with ADAMTS-4 resulted in a time-dependent increase in
NITEGE neoepitope generation [Fig. 1(b)]. In contrast, undigested
aggrecan samples showed no reactivity in this ELISA, demon-
strating the speciﬁcity of this assay to detect aggrecanase-cleavage
of aggrecan.
The ARGS ELISA was developed in order to measure the C-
terminal fragments of aggrecan comprising the G2 domain and the
ARGS neoepitope (ARGN in rat) following aggrecanase-cleavage
within the IGD. In this ELISA, aggrecan fragments are initially
captured with the a-HABR antibody and then detected with theBC3 antibody (that binds to the ARGS/ARGN neoepitope)17. KS
chains present within the IGD of human and bovine aggrecan affect
BC3 antibody binding, warranting a need for deglycosylation of
samples prior to testing them in this ELISA [Fig. 1(c)]. However,
native rat aggrecan (digested with aggrecanase) can be readily
measured with this ELISA because of the lack of KS substitutions in
rat aggrecan19e21 [Fig. 1(c)].
Measurement of aggrecanase-cleaved aggrecan fragments
in cartilage explant cultures using the NITEGE ELISA
Having demonstrated the ability of the NITEGE ELISA to
speciﬁcally measure aggrecanase-cleaved fragments of aggrecan in
vitro, we tested the utility of the ELISA for monitoring aggrecan
degradation in BAC explants that were stimulated with IL-1a. As
shown in Fig. 2(a), treatment with IL-1a resulted in a robust
increase in aggrecan fragment release into the conditionedmedium
at 72 h post treatment. To determine the dependence of this signal
on aggrecanase activity, we tested a broad-spectrum inhibitor of
aggrecanase/MMP activity (CP-669685)29,30 that potently inhibits
puriﬁed aggrecanase-1 and -2 in vitro with an IC50 ofe1 nM. CP-
669685 showed a dose-dependent inhibition of NITEGE fragment
released into the culture medium [Fig. 2(a)]. In order to rule out
a role for MMPs in signal generation in this assay, we tested other
broad-spectrum MMP inhibitors (GM-6001, Marimastat and RS-
130830) that potently inhibit MMPs but have weaker activity
Fig. 3. Time course of aggrecan neoepitope generation in the MIA injection model.
MIA was injected intra-articularly into the right knee joint and saline into the left knee
joint of male Lewis rats. One group of rats was sacriﬁced on day 2, 3, 5 or 7, and
synovial lavage was collected and analyzed by the NITEGE ELISA (a) and ARGS ELISA
(b). n¼ 6 animals/group; S.E.M.: standard error of the mean.
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tested had any effect on aggrecan neoepitope release, demon-
strating the utility of this ELISA for speciﬁcally monitoring aggre-
canase activity [Fig. 2(a)]. These results are consistent with the
increased aggrecanase-mediated cleavage of aggrecan observed
during the initial phase of cartilage damage in the explant culture
system32. The samples were also tested in the DMMB dye-binding
assay which measures sulfated glycosaminoglycans (s-GAGs) such
as KS and chondroitin sulfate released into the tissue culture
medium and the same pattern of inhibition was observed [Fig. 2
(b)]. These data demonstrate a good correlation between the two
assays, with the NITEGE assay being speciﬁc for detecting aggre-
canase-mediated cleavage of aggrecan, while the DMMB assay
provides a general measure of proteoglycan levels (cleaved and
uncleaved) present in the culture medium.
Time course of aggrecan fragment generation in synovial ﬂuid
in the rat MIA model
MIA is a metabolic inhibitor that inhibits the action of the
enzyme glyceraldehyde-3-phosphate dehydrogenase (GAPDH),
resulting in disruption of glycolysis and eventual death of the cells
(chondrocytes, in the case of cartilage)33,34. Cell death in cartilage
results in disruption of the extracellular matrix and the release of
several proteolytic enzymes. Janusz et al.15 performed a biochem-
ical analysis of aggrecan and collagen degradation induced in
response to intra-articular injection of MIA in the knee joints of
rats. Using neoepitope antibodies to the aggrecanase and MMP
cleavage sites in aggrecan and type II collagen, they demonstrated
the presence of aggrecanase and MMP-cleaved neoepitopes of
these matrix proteins in tibial cartilage extracts. Intra-articular
injection of MIA was shown to result in a time-dependent increase
in (1) the loss of proteoglycans from cartilage, (2) generation of
NITEGE (aggrecanase-generated) and VDIPEN (MMP-generated)
neoepitopes, (3) collagen cleavage, and (4) the severity of joint
cartilage degeneration35,36. However, they did not analyze the
synovial ﬂuid from these animals for the presence of released
neoepitope-containing fragments.
The ability of the NITEGE and ARGS neoepitope ELISAs to
measure aggrecan degradation products in cartilage explant
cultures prompted us to utilize these assays to test the synovial
ﬂuid from MIA injected rat knee joints to determine the levels (if
any) of these fragments in the synovial lavage samples. We ﬁrst
looked at the time course of generation of the NITEGE and ARGN
neoepitopes in synovial lavage samples in response to MIA. For this
study, male Lewis rats were injected with MIA into the right knee
joints and saline into the left knee joints. One group of rats was
sacriﬁced on day 2, 3, 5 or 7, and synovial lavage was collected from
both knee joints and analyzed by the two ELISA assays. The synovial
lavage from these animals showed a time-dependent increase in
the MIA-induced generation of fragments containing either the
NITEGE or ARGN neoepitope [Fig. 3(a, b)], with a good window of
neoepitope release seen on day 7.
Inhibition of neoepitope generation by aggrecanase inhibitors
We then tested whether the endogenous generation and release
of these fragments can be inhibited by an aggrecanase inhibitor.
The broad-spectrum aggrecanase/MMP inhibitor CP-669685 was
dosed orally twice a day starting from day 3 onwards and synovial
lavage was collected on day 7, 4 h after the last dose of compound.
Compound treatment was started only on day 3 as we did not
observe an appreciable induction of neoepitope release in the ﬁrst
few days after MIA injection [Fig. 3(a, b)]. The dosing scheme is
outlined schematically in Fig. 4(a). CP-669685 treatment led toa signiﬁcant inhibition of aggrecanase-generated NITEGE neo-
epitope release [Fig. 4(b)]. The MMP inhibitor RS-130830 did not
inhibit NITEGE fragment levels, demonstrating the aggrecanase-
dependent release of this fragment in response to stimulation by
MIA. To further conﬁrm that the neoepitope release is dependent
on aggrecanase activity in the joint, we tested a more selective
aggrecanase inhibitor developed at Lilly (compound A) that inhibits
ADAMTS-4 and ADAMTS-5 with an IC50 of 7.5 and 17 nM, respec-
tively, and is at least a 100-fold less potent in inhibiting a number of
MMPs (Table I). The generation of the NITEGE neoepitopewas dose-
dependently inhibited by the aggrecanase selective inhibitor [Fig. 4
(c)], demonstrating the involvement of aggrecanases in this
process. The synovial lavage samples were also tested in the ARGS
ELISA that measures C-terminal fragments of aggrecan containing
the ARGN neoepitope and the G2 domain, and a similar dose-
dependent inhibition in the levels of this fragment was observed
[Fig. 4(d)]. Treatmentwith a higher dose of compound A (75 mg/kg)
resulted in a 70e80% inhibition of the generation of both neo-
epitopes (data not shown).Measurement of aggrecanase-generated aggrecan fragments
in human OA synovial ﬂuid
Having demonstrated the preclinical utility of the two ELISAs to
measure aggrecanase-dependent markers in rat synovial ﬂuid, we
asked whether these assays would have utility in the clinical situ-
ation to monitor aggrecanase activity in the knee joint. For this, we
tested human synovial ﬂuid samples obtained from patients
undergoing joint replacement surgery. Wewere able to detect both
the NITEGE and ARGS neoepitope-containing fragments in all
patient samples tested [Fig. 5(a, b)]. As would be predicted, the
levels of the fragments varied among the samples. Further, the
signals were completely eliminated by the addition of competing
Fig. 4. Effect of aggrecanase inhibitors in blocking aggrecanase-dependent generation
of aggrecan neoepitopes in the MIA model. n¼ 6 animals/group with MIA (right knee)
or saline (left knee) injected intra-articularly. (a) Outline of the MIA model, showing
the MIA injection and inhibitor dosing schedules. (b) NITEGE ELISA of synovial lavage
obtained from animals treated orally, twice a day, with a broad-spectrum aggrecanase
inhibitor (CP-669685) or an MMP inhibitor (RS-130830) at 30 mg/kg. (c, d) Analysis of
synovial ﬂuid levels of NITEGE (c) and ARGN-containing fragments (d) from animals
treated orally, twice a day with a selective aggrecanase inhibitor (compound A) at 3, 10
and 30 mg/kg. *Statistical signiﬁcance when compared to the vehicle treated group
(p< 0.05). S.E.M.: standard error of the mean.
Fig. 5. NITEGE ELISA (a) and ARGS ELISA (b) of synovial ﬂuid samples obtained from
patients at the time of joint replacement surgery. The samples were treated with
hyaluronidase to reduce viscosity and then deglycosylated to remove the KS and CS
sugars. To determine signal speciﬁcity, competition experiments were performed with
a 16-mer NITEGE-containing peptide or a 22-mer ARGS-containing peptide.
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demonstrating the speciﬁcity of these assays for detecting aggrecan
fragments generated by aggrecanase-cleavage within the IGD.
Although we tested deglycosylated synovial ﬂuid samples in the
NITEGE assay, it was possible to detect native fragments (contain-
ing sugar substitutions) in the synovial ﬂuid using this ELISA (data
not shown).
Discussion
We have developed two novel sandwich ELISAs using an a-
HABR antibody and two neoepitope-speciﬁc antibodies (a-NITEGE
and a-ARGS/ARGN) to monitor aggrecanase-cleavage within the
IGD of aggrecan, and have established a short-term in vivo modelfor aggrecanase activity using these ELISAs. These two assays offer
a signiﬁcant advantage over the previously described ELISA assay16
because of their ability to measure aggrecan degradation products
in rat, which is a commonly used preclinical animal species in OA
drug discovery research. The ELISAs can also be used to screen for
aggrecanase inhibitory compounds in vitro and in cartilage explant
cultures.
The NITEGE ELISA is suitable for measuring aggrecanase-
generated aggrecan fragments in the native state without the need
for deglycosylation since the N-terminal region of aggrecan is
sparsely glycosylated. The ARGS ELISA is useful for measuring C-
terminal fragments of aggrecan comprising the G2 domain and the
ARGS/ARGN neoepitope sequence. The presence of KS side chains
in aggrecan affects BC3 antibody binding. As rat aggrecan lacks KS
substitutions, the ARGS ELISA is ideal for detecting rat aggrecan
fragments.
The presence of the G1 or G2 domain is critical for detecting
a signal in these two ELISAs. Therefore, smaller fragments of
aggrecan that contain the NITEGE sequence but lack the G1 domain
and fragments that contain the ARGS/ARGN neoepitope sequence
but lack the G2 domain because of further proteolytic processing
cannot be detected using these ELISAs. The DIPEN neoepitope that
results from MMP-mediated cleavage of aggrecan within the
IGD37e39 has also been reported to be present along with NITEGE in
the MIA model. NITEGE-containing fragments that are subse-
quently cleaved by MMPs at the VDIPEN341-342FFGVG site to
generate FFGVG—NITEGE fragments will not be detected by the
NITEGE ELISA because of the lack of G1 domain.
Digestion of cartilage explants with ADAMTS-4 and ADAMTS-5
has been shown to induce the release of G1-NITEGE fragments from
the cartilage matrix40. These fragments have also been detected in
human synovial ﬂuid and have been shown to increase with OA,
inﬂammatory joint disease and following acute joint injury41,42. It is
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domain that results in the release of the G1-NITEGE fragment. The
fact that aggrecanase inhibitors signiﬁcantly decrease the release of
the G1-NITEGE fragment [Fig. 4(c)] suggests the possibility that
aggrecanase-cleavage of aggrecan within the IGD (and the subse-
quent release of the ARGN-G2. fragments) could disrupt the
cartilage matrix and result in dissociation of the G1 domain from
the hyaluronan backbone and its subsequent release from the
matrix.
Intra-articular injection of MIA results in an induction of
endogenous aggrecanase activity as measured by an increase in
levels of speciﬁc neoepitope-containing fragments in the synovial
ﬂuid. The neoepitope levels provided a good window for detection
at day 7 in the synovial ﬂuid in our studies, showing good corre-
spondence with the data reported earlier on the levels of NITEGE
fragments present in cartilage15. We did not look at later time
points in the study because we wanted to keep the study duration
short to enable screening of multiple compounds in succession.
Using broad-spectrum as well as selective inhibitors of aggrecanase
activity, we have demonstrated the ability of the ELISA assays to
measure speciﬁc products of aggrecanase-cleavage in the synovial
ﬂuid and the potential utility of this model to screen for compounds
that inhibit aggrecanases. In addition, this model evaluates the
bioavailability of compounds dosed systemically, with a pharma-
codynamic effect observed in the joint ﬂuid. However, we did
not attempt to measure compound levels in synovial ﬂuid or
cartilage and the lack of effect of a compound in blocking neo-
epitope generation could result from its inability to penetrate
cartilage efﬁciently.
An earlier study utilizing intra-articular injection of MIA
depended on extraction of rat cartilage and analysis of the neo-
epitope-containing fragments by Western blotting15. The ELISA
approaches described in this study offer signiﬁcant advantages
over the previous study because the quick readout and quanti-
tative nature of ELISA detection enables higher throughput
testing of compounds to choose the best ones for further testing
in resource-intensive disease models of OA. We have also
demonstrated the utility of the neoepitope ELISA assays to
quantify aggrecan degradation products in human synovial ﬂuid
samples, suggesting the potential for these assays to serve as
drug activity biomarker assays and thereby provide an early
indication of drug activity in the clinic. We were, however, not
able to detect these neoepitope-containing fragments in human
serum or urine. It is possible that the sensitivity of these ELISAs
are likely not sufﬁcient to detect the presumably low levels of
epitopes present in systemic circulation and in urine. Based on
our studies, we cannot tell whether there is a difference in the
kinetics of release of the ARGS- and NITEGE-containing frag-
ments into the synovial ﬂuid. It is tempting to speculate that the
ARGS fragments would get released immediately upon aggreca-
nase-mediated cleavage within the IGD and that the release of
G1-NITEGE fragments would occur subsequently. Such a differ-
ence would suggest that high levels of ARGS-containing frag-
ments in the synovial ﬂuid would represent an early stage of the
disease, whereas high levels of the NITEGE-containing fragment
would represent a somewhat later stage during the progression
of the disease. Further studies in disease models in animals, and
characterization of synovial ﬂuids obtained from well annotated
patient populations are needed to assess the utility of these
markers as predictors of early and late stages of progression of
the disease.
The NITEGE and ARGS/ARGN neoepitope sequences are fairly
well conserved in many mammalian species (human, rat, cattle,
sheep, dog, rabbit, and horse)43 implicating the utility of these two
ELISAs to measure aggrecanase-generated aggrecan degradationproducts in these animals in the basal state and during the
progression of joint damage during naturally occurring disease or
after surgical, chemical or inﬂammatory insults.
In summary, we have developed two novel ELISAs to detect
aggrecan fragments generated by aggrecanase-cleavage within the
IGD and have demonstrated their utility for the development of
a short-term pharmacodynamic model for in vivo evaluation of
compounds that inhibit aggrecanase activity. These assays would
serve as useful tools for the identiﬁcation of aggrecanase inhibitors
and other disease modifying osteoarthritic drugs.
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